Navigation Links
Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
Date:5/9/2011

r of 2011.  
  • On March 22, Auxilium announced that it has granted Asahi Kasei Pharma exclusive rights to commercialize XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Japan. Asahi Kasei Pharma will be primarily responsible for the clinical development, regulatory and commercialization activities for XIAFLEX in Japan.  The Company received a $15 million up-front payment from Asahi Kasei Pharma in the first quarter of 2011.
  • The Company exceeded the target enrollment for the double-blind placebo-controlled phase III program of XIAFLEX for the treatment of Peyronie's disease.  In excess of 800 patients have been enrolled in the two double-blind placebo-controlled phase III trials.  Top-line data is expected in the second quarter of 2012.
  • Beginning January 1, a new XIAFLEX-specific J-code (J0775) was available for use in the U.S. to identify XIAFLEX for obtaining reimbursement from Medicare, Medicaid and commercial health plans.
  • On April 11, the Company announced that it will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc. (Pfizer), following the first sale of XIAPEX in the United Kingdom.  Auxilium is eligible to receive up to $30 million in additional regulatory milestone payments for this indication, which will be paid in $7.5 million increments, following Pfizer's first sale of XIAPEX in each of the remaining major markets of the EU.  

  • Testim:

  • Worldwide revenues for Testim were $46.1 million, up 4% over the first quarter of 2010.
  • According to IMS Health, Inc., a pharmaceutical market research firm ("IMS"), over 172,000 total prescriptions for Testim were dispensed in the first quarter of 2011, a growth of 9% over the first quarter of 2010.
  • Total Testim units reported by IMS on a prescription basis exceeded total Testim units sold to customers during the first quarter of 2011, as wholesalers reduced their d
    '/>"/>

  • SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
    2. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
    3. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
    4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    5. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
    6. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
    7. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
    8. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
    9. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
    10. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
    11. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... TEL AVIV, Israel , July 23, 2014 ... Ltd ., a portfolio company of Trendlines ... with one of Israel,s ... (Logo: http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines ... from plant pulp waste, with additional nanoparticles to ...
    (Date:7/23/2014)... , July 23, 2014 regulated information -- UCB ... and development pipeline with positive topline results from ... . This study was designed to evaluate the efficacy ... 200 mg/day, without titration) compared to placebo, as ... partial-onset seizures, not fully controlled despite treatment with ...
    (Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
    (Date:7/23/2014)... July 23, 2014 OncLive® is ... Center has joined its Strategic Alliance Partnership program. ... Partnership program, UNC Lineberger will have the opportunity ... awareness of its cutting-edge research initiatives, community-directed cancer ... Lineberger will work with OncLive to educate their ...
    Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
    ... , CORALVILLE, Iowa, Nov. 17 Vivakor, Inc. (OTC ... approved a dividend of shares of common stock of HealthAmerica, ... of the outstanding common stock. Each Vivakor shareholder will ... for each share of Vivakor common stock beneficially owned on ...
    ... Neuralstem, Inc. (NYSE Amex: CUR ) today provided a financial ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO ) , ... loss of $5,096,983, or $0.15 per share, compared with a net ... period. The increase was due to a non-cash charge related to ...
    ... LEIDEN, The Netherlands, November 17 ... with Actelion Pharmaceuticals Ltd,Erasmus Medical Centre and Maastricht ... hypertension (high blood pressure) and associated vascular,complications such as ... novel action mechanisms, new drugs may be discovered with,the ...
    Cached Biology Technology:Vivakor, Inc. Announces Stock Dividend 2Vivakor, Inc. Announces Stock Dividend 3Vivakor, Inc. Announces Stock Dividend 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 2Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 3Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 5Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 6Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 7New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications 2
    (Date:7/23/2014)... rely on sophisticated equipment, trained personnel, and detection ... against terrorist attacks. A revolutionary new electronic chip ... their job much easier. , The groundbreaking nanotechnology-inspired ... Aviv University ,s School of Chemistry and Center ... Herzliya company Tracense, picks up the scent of ...
    (Date:7/23/2014)... and blood-brain barrier damage appear after cerebral ... Matrix metalloproteinase-9 is able to degrade the ... cerebral blood vessels and to mediate extracellular ... colleagues from the First Affiliated Hospital of ... induced cerebral infarction in stroke-prone spontaneously hypertensive ...
    (Date:7/23/2014)... Scientists with the NH Agricultural Experiment Station are working ... after new research based on genetic monitoring has found ... New England have become more isolated and seen a ... endangered New England cottontail is now is at risk ... Agricultural Experiment Station researchers at the University of New ...
    Breaking Biology News(10 mins):Nano-sized chip "sniffs out" explosives far better than trained dogs 2UNH NHAES researchers work to save endangered New England cottontail 2UNH NHAES researchers work to save endangered New England cottontail 3
    ... The ubiquitous and usually harmless E. coli bacterium, which ... has more than 1,000 of them involved in metabolism ... genes would theoretically be capable of generating a huge ... report in the Dec. 27 issue of Proceedings of ...
    ... medical doctor. Yet he is seen as a hero by ... was diagnosed with terminal lung cancer. , "In 2000 he ... months to live," said Pardini, a professor of biochemistry and ... University of Nevada, Reno. "But five years later, he ...
    ... great challenges for treating Parkinson's diseases and other neurodegenerative disorders ... , The brain is a complex organ with many different ... a protective barrier erected by blood vessels and glial cells ... the delivery of most drugs from the bloodstream. , But ...
    Cached Biology News:How E. coli bacterium generates simplicity from complexity 2How E. coli bacterium generates simplicity from complexity 3The nude mouse tale: Omega-3 fats save the life of a terminal cancer patient 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 3
    ... are rigid macroporous hydrophilic media. The rigid ... moderate pressures, while the macroporous beads enhance ... matrix reduces nonspecific binding. Macro-Prep High Q ... with very high flow rates and resolution. ...
    ... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
    ... The IDS 25-Hydroxy Vitamin D kit ... quantitative determination of 25-hydroxyvitamin D (25-OH ... human serum or plasma. Our patented ... of solvent precipitation and centrifugation and ...
    ... A multi-purpose, high gel-strength agarose suitable for ... from conventional constant field to Pulsed Field ... gel strength and exclusion limits, Multi ABgarose ... reduced running times. This in turn means ...
    Biology Products: